NVO Stock Summary and Trading Ideas (Novo Nordisk A/S | NYSE:NVO)

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S trades on the NYSE stock market under the symbol NVO.

As of April 17, 2026, NVO stock price declined to $40.52 with 11,662,309 million shares trading.

NVO has a beta of 1.45, meaning it tends to be more sensitive to market movements. NVO has a correlation of 0.09 to the broad based SPY ETF.

NVO has a market cap of $179.85 billion. This is considered a Large Cap stock.

Last quarter Novo Nordisk A/S reported $12 billion in Revenue and $1.00 earnings per share. This beat revenue expectation by $255 million and exceeded earnings estimates by $.11.

In the last 3 years, NVO traded as high as $148.15 and as low as $35.12.

The top ETF exchange traded funds that NVO belongs to (by Net Assets): PVAL, PPH, AVDE, PID, WCMI.

NVO has underperformed the market in the last year with a return of -32.6%, while the SPY ETF gained +36.5%. In the last 3 month period, NVO fell short of the market, returning -32.9%, while SPY returned +2.9%. However, in the most recent 2 weeks NVO has outperformed the stock market by returning +9.6%, while SPY returned +8.3%.

NVO support price is $39.95 and resistance is $41.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVO shares will trade within this expected range on the day.